Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
UC
UCB.BR
UC
UCB SA
UCB.BR
News
·
Is UCB (ENXTBR:UCB) Undervalued As It Expands Its Biologics Campus In Georgia?
Mkt Cap
$39.01B
Volume
324.45K
Next Earnings
February 25th
Chart
Financials
Earnings
News
About
Insider
Filings
Is UCB (ENXTBR:UCB) Undervalued As It Expands Its Biologics Campus In Georgia?
UCB (ENXTBR:UCB) just dedicated the future site of a large biologics manufacturing campus in Gwinnett County, Georgia, marking a roughly €2b U.S. expansion that investors may view as a long-horizon capacity build. For context, UCB's €203.5 share price comes after a 90 day share p…
finance.yahoo.com · Oct 10, 2026
UCB (UCBJY) Upgraded to Buy: Here's Why
UCB SA (UCBJY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture…
finance.yahoo.com · Sep 18, 2026
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
On Monday, President Trump announced that his administration has signed separate drug-pricing agreements with nine mid-sized pharmaceutical companies to lower drug prices in the country. These companies include Alcon, Astellas Pharma ALPMY, BeOne Medicines ONC, BridgeBio Pharma B…
finance.yahoo.com · Sep 1, 2026
Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms
(Bloomberg) -- The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd. Most Read from Bloomberg Nvidia to Invest $3.5 Billion in Chipmaker MediaTe…
finance.yahoo.com · Aug 31, 2026
UCB SA (UCBJF) (H1 2026) Earnings Call Highlights: Record Sales and Strategic Expansion Drive ...
This article first appeared on GuruFocus. Total Net Sales: Grew 23% to EUR4.1 billion in H1 2026. Total Revenue: Increased 22% (27% at constant rate) to EUR4.3 billion. Adjusted Gross Profit: Reached EUR3.5 billion, up 27% (33% at constant exchange rate), with gross margin improv…
finance.yahoo.com · Aug 1, 2026
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Biogen Inc. Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus …
finance.yahoo.com · Jun 4, 2026
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
Biogen Inc.; UCB Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of care Findings showed…
finance.yahoo.com · Jun 1, 2026
Is It Too Late To Consider UCB (ENXTBR:UCB) After A 195% Three Year Surge?
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Investors may be wondering if UCB's share price still reflects good value after a strong run, or if most of the opportunity is already pri…
finance.yahoo.com · Apr 24, 2026
A Look At UCB (ENXTBR:UCB) Valuation After Neurology Conference Data And Real World Results
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Conference data puts UCB’s neurology pipeline in focus UCB (ENXTBR:UCB) is in the spotlight after presenting 21 neurology abstracts at the American Academy of Neurol…
finance.yahoo.com · Apr 24, 2026
UCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know
Investors might want to bet on UCB SA (UCBJY), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely…
finance.yahoo.com · Apr 15, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
UC
UCB.BR
UCB SA
Buy
Sell
Market
Limit
Soon
UCB.BR
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any UCB.BR yet.
Related Tickers
Earnings